Investors

Biostage is an evolving leader in regenerative medicine, patient-specific stem cell therapy, and tissue engineering. The company develops customized bioengineered organ implants designed to restore organ function of the esophagus, trachea and bronchus damaged by disease or trauma.

Biostage has built a dedicated internal team of materials scientists, engineers and biologists who are working with our external collaborators to bring our products to the patients who need them as quickly as possible.

Stock Information

OTCQBBSTG

Press Releases

Email Alerts

May 14, 2019

Biostage Reports First Quarter 2019 Financial Results

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...

May 8, 2019

Biostage to Host Conference Call to Discuss First Quarter 2019 Financial Results and Business Update

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...

Mar 28, 2019

Biostage Reports 2018 Financial Results

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...

More >

Events

Biostage to Host Conference Call to Discuss First Quarter 2019 Financial Results and Business Update

Tuesday, May 14, 2019

9:00am - 10:00am EDT

Biostage to Host Conference Call to Discuss 2018 Financial Results and Business Update

Thursday, March 28, 2019

9:00am - 10:00am EDT

Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Operations

Thursday, November 8, 2018

9:30am - 10:30am EST

Biostage, Inc.
84 October Hill Road
Suite 11
Holliston, Massachusetts 01746
United States